It cites clinical trial data for its molecules (15 to 20% for semaglutide, 20 to 22% for tirzepatide from SURMOUNT-1 and STEP)
Expansion in obesity management, oral GLP-1 formulations, emerging market penetration, next-generation dual-agonists, and digital health integration offer significant growth opportunities
A structural basis for amylin receptor phenotype
Novo Nordisk, the company behind both Ozempic and Wegovy, has seen its stock price skyrocket in recent years
Supplements promising to give you the same results as prescription medications are overhyped
Try a different medication: If you want to keep taking a weight-loss medication but the cost or side effects make GLP-1s a no-go, there are other options out there such as Qsymia and Contrave and your clinician may be able to recommend and prescribe a different weight-loss medication